Amryt Pharma (LON:AMYT) “Speculative Buy” Rating Reiterated at Beaufort Securities; CVR Partners LP Has 0.87 Sentiment

CVR Partners, LP produces, distributes, and markets nitrogen fertilizer products in North America. The company has market cap of $396.49 million. It provides ammonia products for agricultural and industrial customers; and urea ammonium nitrate products for agricultural customers. It currently has negative earnings. CVR GP, LLC serves as the general partner of the company.

Amryt Pharma (LON:AMYT) stock “Speculative Buy” was reaffirmed by Analysts at Beaufort Securities in analysts note released on Wednesday morning.

Among 2 analysts covering Amryt Pharma (LON:AMYT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amryt Pharma has GBX 70 highest and GBX 49 lowest target. GBX 65’s average target is 231.63% above currents GBX 19.6 stock price. Amryt Pharma had 25 analyst reports since June 10, 2016 according to SRatingsIntel. Stifel Nicolaus maintained the shares of AMYT in report on Monday, April 24 with “Buy” rating. The firm has “Speculative Buy” rating given on Friday, May 26 by Beaufort Securities. As per Wednesday, January 31, the company rating was maintained by Beaufort Securities. The stock of Amryt Pharma plc (LON:AMYT) has “Buy” rating given on Monday, February 6 by Stifel Nicolaus. Beaufort Securities maintained the shares of AMYT in report on Tuesday, January 9 with “Speculative Buy” rating. On Tuesday, February 7 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The firm has “Speculative Buy” rating given on Thursday, August 31 by Beaufort Securities. The stock of Amryt Pharma plc (LON:AMYT) earned “Speculative Buy” rating by Beaufort Securities on Monday, September 4. The rating was maintained by Beaufort Securities on Tuesday, September 20 with “Speculative Buy”. As per Thursday, December 21, the company rating was maintained by Beaufort Securities.

The stock decreased 2.24% or GBX 0.45 during the last trading session, reaching GBX 19.6. About 9,926 shares traded. Amryt Pharma plc (LON:AMYT) has 0.00% since January 31, 2017 and is . It has underperformed by 16.70% the S&P500.

Amryt Pharma plc, a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of medicines for the treatment for patients with rare and orphan diseases. The company has market cap of 53.86 million GBP. The Company’s lead product includes Episalvan, a prescription pharmaceutical product used for the treatment of partial-thickness wounds in adults. It currently has negative earnings. The firm also offers Lojuxta for the treatment of homozygous familial hypercholesterolemia and to reduce lipoprotein in adults; and Imlan, a skin care product with regenerative and anti-inflammatory properties.

The stock increased 0.57% or $0.02 during the last trading session, reaching $3.5. About 260,817 shares traded. CVR Partners, LP (UAN) has declined 44.11% since January 31, 2017 and is downtrending. It has underperformed by 60.81% the S&P500.

Analysts await CVR Partners, LP (NYSE:UAN) to report earnings on February, 15. They expect $-0.14 EPS, down 7.69% or $0.01 from last year’s $-0.13 per share. After $-0.28 actual EPS reported by CVR Partners, LP for the previous quarter, Wall Street now forecasts -50.00% EPS growth.